BCRX(BioCryst Pharmaceuticals, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $157.17M | $270.83M | $331.41M | $450.71M | $874.84M |
| 毛利润 | $149.94M | $264.42M | $326.93M | $438.44M | $855.76M |
| 营业利润 | −$177.72M | −$148.44M | −$103.71M | −$2.54M | $340.99M |
| 净利润 | −$184.06M | −$247.12M | −$226.54M | −$88.88M | $263.86M |
| 经营现金流 | −$142.16M | −$161.85M | −$95.14M | −$52.02M | $347.37M |
| 自由现金流 | −$144.54M | −$163.20M | −$97.31M | −$53.14M | $344.90M |
| 摊薄每股收益 | $-1.03 | $-1.33 | $-1.18 | $-0.43 | $1.21 |